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The glycoprotein nature of the ligand binding subunit of photoaffinity-labeled striatal D, receptors was investigated. 
Upon photolysis, [rZ51]N-azidophenethylspiperone covalently incorporated into a major band of M, 94000 with an appro- 
priate pharmacological profile for D, receptors as assessed by autoradiography following SDS-polyacrylamide gel elcc- 
trophoresis. The exoglycosidase, neuraminidase, altered the electrophoretic mobility of the 94 kDa labeled band to 54 
kDa with a slight modification in the binding affinity of PH]spiperone. Endoglycosidase treatment (glycopeptidase-F) 
produced a further increase in the mobility of the 94 kDa peptide to _ 43 kDa. A smaller specifically photolabeled D, 
receptor peptide of 34 kDa does not contain terminal sialic acid but is an N-linked glycoprotein as assessed by lectin 
affinity chromatography and susceptibility to digestion by glycopeptidase-F to a peptide of -23 kDa. 
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1. INTRODUCTION 
The dopamine D2 receptor has been identified 
and classified on the basis of its ability to inhibit 
adenylate cyclase activity and bind or respond to 
specific dopaminergic agonists and antagonists 
(reviews [l-3]). The recent development of specific 
photoaffinity labels for D2 dopamine receptors, by 
us and others (see [3]) now allows for the analysis 
of these membrane proteins at the molecular level. 
Numerous proteins including many neurotrans- 
mitter receptors are glycoproteins [4-91. In this 
communication, we demonstrate the glycoprotein 
nature of the striatal Dt receptor ligand binding 
subunit by enzymatic digestion of photolabeled 
receptor proteins. 
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2. MATERIALS AND METHODS 
[“‘I]NAPS (2200 Ci/mmol) was purchased from New 
England Nuclear and [3H]spiperone (85 Ci/mmol) from Amer- 
sham. Neuraminidase (purified type X from (Clostridium per- 
fringens), a-mannosidase (from jack bean), and Nonidet P-40 
were from Sigma. Purified glycopeptidase-F (peptide-N4 [N- 
acetyl-fl-glucosaminyl]asparagine amidase) from Flavo- 
bacterium meningosepticum was from Boehringer-Mannheim. 
All other materials were from sources described in [lo,1 11. 
2.1. Membrane preparation 
Striata, dissected from partially thawed canine brains (Pel 
Freez, Rogers, AR) were Teflon-glass homogenized in 20 vols 
of 25 mM Tris-HCl buffer containing 250 mM sucrose and the 
following protease inhibitors: 20 mM EDTA, 5 pg/ml leupep- 
tin, 15 #g/ml benzamidine, 5 yg/ml soybean trypsin inhibitor 
and 1 mM PMSF (pH 7.4 at 4°C). Homogenates were cen- 
trifuged at 600 x g for 10 min and the supernatant recentri- 
fuged at 48000 x g for 20 min. The resulting pellet was 
resuspended in 25 mM Tris-HC1 buffer containing 120 mM 
NaCl and protease inhibitors to yield a final protein concentra- 
tion of approx. 2 mg/ml. 
2.2. Photoaffinity labeling 
Membranes (1 ml) were routinely incubated (in the dark) with 
[‘*‘I]NAPS (50 pM final concentration) in the absence or 
presence of 1 pM (+)-butaclamol or other dopaminergic agents 
(as indicated) for 90 min at 22°C in a final volume of 10 ml at 
-50 pM Dz receptor and processed for photolysis as described 
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[12]. Samples (1 ml) were irradiated for 35 s as described [lo], 
transferred to 1.5 ml Eppendorf microfuge tubes and 
sedimented at 12ooO x g for 10 min. 
2.3. Exoglycosidase treatments 
Photoaffinity-labeled membranes were washed twice in 30 ml 
of 100 mM sodium acetate buffer (pH 5 at 22°C) containing 
100,uM PMSF. Pellets were resuspended in buffer 
(0.5-1.0 mg/ml) and incubated with neuraminidase (up to 
2 U/ml) at 37°C for the indicated time periods. For cy- 
mannosidase treatment, photolabeled receptors were washed in 
50 mM sodium citrate buffer (pH 4.5 at 22°C) containing 
1OOrM PMSF and incubated with up to 12 U/ml of cy- 
mannosidase for 24 h at 25°C. Following incubation, mem- 
branes were pelleted, washed once with 25 mM Tris-HCl buffer 
and prepared for SDS-PAGE as described in [lo]. 
2.4. Endoglycosidase treatment 
Photolabeled and neuraminidase-treated membranes were 
washed twice in 200 mM sodium phosphate buffer (pH 8.1 at 
25’C) containing 2.5 mM EDTA, and incubated with 0.5% 
SDS and 100 mM ,8mercaptoethanol for 60 min at 22°C. Ali- 
quots (30 pl, -500,ug protein) were incubated with Nonidet 
P-40 (1.25% final concentration), PNGase-F (up to 60 U/ml) 
and 50 mM EDTA for 20 h at 37°C in a volume of 60 ~1 (final 
concentration of SDS < 0.17%). Samples were centrifuged at 
12000 x g for 10 min, the supernatant aspirated and samples 
A 
Mr 
180- 
added to SDS-sample buffer (containing 20% SDS) for 120 min 
at 22°C. 
2.5. DZ receptor solubilization 
Photolabeled membranes were solubilized in 1% digitonin 
(2 ml) and applied to a 2 ml WGA-Sepharose column at 4°C as 
described in [lo, 111. Absorbed receptors were specifically 
eluted with 150 mM N-acetylglucosamine. Samples were then 
lyophilized and processed for electrophoresis as described 
above. 
2.6. Ligand binding 
[3H]Spiperone binding to Dz receptors and computer assisted 
analysis of all binding data (LIGAND) were as described 
[lO,ll]. 
2.7. SDS-PAGE and autoradiography 
Prior to electrophoresis, samples were dissolved in SDS- 
sample buffer as described [lo] for 60-120 min at 22OC. Ali- 
quots (-100-300 pg protein) were loaded on 1.5 mm-thick slab 
gels containing a 10 or 12% acrylamide separating gel and elec- 
trophoresed overnight. Gels were dried, exposed to Kodak 
XAR-5 film with intensifying screen for 20 h at -70°C and 
manually developed with Kodak D-19 developer. Prestained 
molecular mass standards (Sigma) were used to visualize protein 
migration. 
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Fig.1. Pharmacological specificity of [iz51]NAPS photoincorporation into canine striatal membranes. Striatal homogenates were 
incubated with [iz51]NAPS alone or with dopaminergic agents, photolyzed and prepared for electrophoresis on a 10% acrylamide gel 
as described in section 2. The results shown are identical with at least three other experiments. Molecular mass standards are shown 
on the left (x 1000). Eticlo., eticlopride; Ket., ketanserin; NPA, N-propylnorapomorphine; NE, noradrenaline; BTC, butaclamol. 
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3. RESULTS AND DISCUSSION 
As illustrated in fig.1 (A and B), [“‘IINAPS 
photoincorporated into a striatal peptide of M, 
94000 as assessed by autoradiography following 
SDS-PAGE. The broad band at M, 94000 
represents the ligand binding subunit of the DZ 
receptor since photoaffinity labeling is stereoselec- 
tively blocked by dopaminergic antagonists and 
agonists with an appropriate pharmacological pro- 
file for D2 receptors. In addition, a peptide of MI 
-36000-34000 revealed a similar pharmacological 
profile for Da receptors. The stoichiometry of 
labeling of the 94 kDa and 34 kDa peptide was 
-3 : 1. Whether the peptide at M, 34000 represents 
a proteolytic degradation product of the peptide at 
Mr 94000 is still unknown, although under our 
assay conditions this peptide is always seen either 
in the absence or presence of protease inhibitors 
(not shown). Minor specifically labeled peptides 
(e.g. M, 66000) were inconsistently observed as 
well as a non-specifically labeled protein at Mr 
51000. 
The carbohydrate nature of the ligand binding 
subunit(s) of the D2 receptor was assessed by the 
exoglycosidase, neuraminidase, which specifically 
cleaves terminal sialic acids. As seen in fig.2, 
neuraminidase altered the electrophoretic mobility 
of the peptide at Mr 94000 to Mr -54000 without 
affecting the migration of the photolabeled peptide 
at M, 34000. At present, it is unclear whether the 
change in the migration pattern of the 94 kDa pep- 
tide induced by neuraminidase is the result of the 
cleavage of a large quantity of receptor-associated 
sialic acids or simply due to the removal of 
negatively charged carbohydrate moieties interfer- 
ing with the protein denaturing effects of SDS. In 
any event, it should be noted that not all of the 
photolabeled protein at I@ 94000 is digested by 
neuraminidase. Both the 94 kDa and 34 kDa la- 
beled peptides are glycoproteins since they absorb 
to and specifically elute from WGA-Sepharose 
(fig.3) prior to or following neuraminidase treat- 
ment suggestive of a poly(N-acetyllactosamine)- 
type glycopeptide [131. Treatment of photolabeled 
membranes with up to 12 U/ml of cY-mannosidase 
did not alter the mobility of SDS-PAGE-separated 
peptides (Mr 94000 and 34000), although a minor 
peptide of M, -58000 was observed (not shown). 
These data suggest hat the ligand binding subunit 
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of Dz receptors contains terminal sialic acid with 
few terminal high mannose chains and is consistent 
with the observation that solubilized D2 receptors 
absorb to and are specifically eluted from WGA- 
Sepharose but not concanavalin-A columns (see 
above and [10,14,15]). 
Following neuraminidase, the peptide at M, 
54000 appears to bind the selective D2 receptor an- 
tagonist, 13H]spiperone (fig.4B) in a saturable 
manner without significantly affecting receptor 
density (control: 5.5 f 0.2 pM; treated 5.2 f 
Neuraminidase 
Mr I 
2 u/ml 0.5 u/ml 
116 - 
84- 
58- 
48- 
36- 
26- 
Fig.2. Effect of neuraminidase on the SDS-PAGE migration 
pattern of photolabeled DZ receptors. [‘251]NAPS-labeled 
membranes were prepared for enzyme treatment as described in 
section 2. Neuraminidase was added at the indicated 
concentrations for various periods of time at 37°C. Control 
samples were incubated at 37°C for 6 h in the absence or 
presence of 1 ,uM (+)-butaclamol. Included in this gel is a lane 
demonstrating non-specific labeling for neuraminidase-treated 
receptors. Following treatment, membranes were prepared and 
subjected to SDS-PAGE as described in section 2 using a 12% 
acrylamide gel. Abbreviations used are as in fig.1. 
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Fig.3. Effect of neuraminidase on WGA-lectin affinity eluates. 
[‘ZSI]NAPS-labeled receptors were prepared for enzyme 
treatment as described in section 2. Photolabeled membranes 
were incubated without (control) or with 2 U/ml neuraminidase 
for 30 min at 37°C. Membranes were washed, solubilized with 
1% digitonin and centrifuged. The supernatant (2 ml) was 
applied to a column of WGA-Sepharose equilibrated with 
50 mM Tris-HCl and 0.1 Vo digitonin at pH 7.4 at 4”C, recycled 
and washed with 20 ml of the same buffer. Absorbed protein 
was eluted by the addition of 150 mM N-acetylglucosamine 
(WGA eluate) in 0.05% digitonin. Equal amounts of protein 
(-250 cg) from solubilized and eluted samples were lyophilized 
and subjected to electrophoresis on 10% (control) or 12% 
(neuraminidase) gels and autoradiography. 
0.4 PM) as determined by saturation analysis. The 
affinity of [3H]spiperone for the peptide at A4, 
54000 was reduced by -2-3-fold from 110 f 6 pM 
to 288 f 12 pM. It is of interest to note that the 
brief exposure of the membrane (20 min) to pH 5.0 
irreversibly inactivated -70% of the original 
receptor population (Bmax -20 PM). This effect 
was not prevented by prior occupancy of the recep- 
tor by DZ receptor antagonists such as (+)- 
butaclamol or spiperone. 
66 
m 
Fig.4. Effect of neuraminidase on [3H]spiperone binding activity. Striatal membranes were prepared for enzyme treatment as described 
in section 2. Neuraminidase (B) was added at a concentration of 2 U/ml and incubated for 20 min at 37°C. Control membranes (A) 
were treated in an identical fashion but without neuraminidase. Following treatment, membranes were extensively washed in Tris-HCl 
buffer containing 120 mM NaCl, pH 7.4, at 22’C and assayed for Dz receptor activity with [‘Hlspiperone (10-1800 PM) as described. 
Data were analyzed by LIGAND and are representative of two similar experiments. (Inset) Control and neuraminidase-treated tissue 
were incubated with [r2’I]NAPS (50 PM), in the absence or presence of (+)-butaclamol (1 pM), photolyzed and prepared for SDS- 
PAGE and autoradiography as described in section 2. 
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Fig.5. Sequential neuraminidase-PNGase-F 
a b cd 
treatment. 
[‘L’I]NAPS-labeled membranes were prepared for enzyme 
treatment as described. Aliquots were incubated with PNGase- 
F for 20 h at 37°C as follows. Lanes: a, control, 2 U/ml 
neuraminidase; b, 2 U/ml neuraminidase and 10 U/ml 
PNGase-F; c, 2 U/ml neuraminidase and 60 U/ml PNGase-F; 
d, same as lane c except photolabeling in the presence of 1 FM 
(+)-butaclamol. Following treatment, aliquots were prepared 
for SDS-PAGE and autoradiography as described. 
Complete removal of N-linked carbohydrate by 
sequential neuraminidase and endoglycosidase 
treatment with PNGase F revealed that the major 
photolabeled peptide of MI 94000 representing the 
ligand binding subunit of the DZ receptor resides in 
a peptide of A4, -43000 (fig.5). The 34 kDa la- 
beled fragment following PNGase F treatment had 
migrated to -23 kDa with an intermediate labeled 
protein of 26 kDa. Similar results were obtained 
with endoglycosidase-F (NEN) at pH 8.0 (not 
shown). Whether the polypeptide at A4, 26000 
represents an incompletely deglycosylated receptor 
fragment or a proteolytic breakdown product is 
unknown at present. 
In summary, these data indicate that the ligand 
binding subunit of DZ receptors is associated with 
sialic acid/acetylglucosamine carbohydrate chains 
and suggests that the molecular mass of the 
Dz-binding subunit is greatly overestimated ue to 
receptor-associated carbohydrate. Moreover, the 
differential susceptibility of the peptides at Mr 
94000 and 34000 to digestion by exo- and endo- 
glycosidases uggests that the D2 receptor is com- 
posed of two distinct glycosylated protein subunits 
and is possibly a dimer of A& 23000 (x 2). The 
functional significance of these receptor-associated 
carbohydrate groups for the expression and 
maintenance df Dz receptor activity is unknown at 
present. 
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